2530. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dose Selection for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Community-Acquired Bacterial Pneumonia (CABP)

Sujata M Bhavnani,Anthony J Rinaldo,Marc Engelhardt,Christopher M Rubino,Karine Litherland,Paul G Ambrose,Jennifer Smart,Mark E Jones,Leonard R Duncan,Jeffrey P Hammel

doi:10.1093/ofid/ofad500.2148

2530. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dose Selection for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Community-Acquired Bacterial Pneumonia (CABP)

Sujata M Bhavnani, Anthony J Rinaldo + Show 8 more

Open Access

PDF Available

https://doi.org/10.1093/ofid/ofad500.2148

Copy DOI

Export

Save

Cite

Journal: Open Forum Infectious Diseases	Publication Date: Nov 27, 2023
License type: CC BY 4.0

Affiliation: Institute for Clinical Pharmacodynamics (United States), Basilea Pharmaceutica (Switzerland), JMI Laboratories

#Acute Bacterial Skin #Acute Bacterial Skin And Skin Structure Infections #Skin Structure Infections #Community-acquired Bacterial Pneumonia #Bacterial Skin Infections #Pharmacokinetic-Pharmacodynamic Target #Acute Bacterial Infections #Acute Skin #Acute Infections #Bacterial Infections

Abstract
Full-Text PDF
Similar Papers

Abstract

Listen

2530. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dose Selection for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Community-Acquired Bacterial Pneumonia (CABP)

Full Text

Published Version (Free)

View/Download pdf

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Open Forum Infectious Diseases

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

2530. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dose Selection for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Community-Acquired Bacterial Pneumonia (CABP)